ATE472102T1 - Verfahren zur vorhersage von anomalien des lipidmetabolismus - Google Patents
Verfahren zur vorhersage von anomalien des lipidmetabolismusInfo
- Publication number
- ATE472102T1 ATE472102T1 AT04808108T AT04808108T ATE472102T1 AT E472102 T1 ATE472102 T1 AT E472102T1 AT 04808108 T AT04808108 T AT 04808108T AT 04808108 T AT04808108 T AT 04808108T AT E472102 T1 ATE472102 T1 AT E472102T1
- Authority
- AT
- Austria
- Prior art keywords
- compound
- predicting
- lipidosis
- abnomals
- lipid metabolism
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 2
- 230000037356 lipid metabolism Effects 0.000 title 1
- QIAFMBKCNZACKA-UHFFFAOYSA-N N-benzoylglycine Chemical compound OC(=O)CNC(=O)C1=CC=CC=C1 QIAFMBKCNZACKA-UHFFFAOYSA-N 0.000 abstract 4
- 150000001875 compounds Chemical class 0.000 abstract 4
- UTYVDVLMYQPLQB-UHFFFAOYSA-N phenylacetylglycine Chemical compound OC(=O)CNC(=O)CC1=CC=CC=C1 UTYVDVLMYQPLQB-UHFFFAOYSA-N 0.000 abstract 4
- 208000000501 Lipidoses Diseases 0.000 abstract 3
- 206010024585 Lipidosis Diseases 0.000 abstract 3
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 abstract 2
- 241000124008 Mammalia Species 0.000 abstract 2
- JFLIEFSWGNOPJJ-JTQLQIEISA-N N(2)-phenylacetyl-L-glutamine Chemical compound NC(=O)CC[C@@H](C(O)=O)NC(=O)CC1=CC=CC=C1 JFLIEFSWGNOPJJ-JTQLQIEISA-N 0.000 abstract 2
- 230000002503 metabolic effect Effects 0.000 abstract 2
- 230000037353 metabolic pathway Effects 0.000 abstract 2
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 abstract 2
- 238000003745 diagnosis Methods 0.000 abstract 1
- 238000002405 diagnostic procedure Methods 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000001939 inductive effect Effects 0.000 abstract 1
- 210000004962 mammalian cell Anatomy 0.000 abstract 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/92—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving lipids, e.g. cholesterol, lipoproteins, or their receptors
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
- G01N33/5038—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects involving detection of metabolites per se
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/04—Endocrine or metabolic disorders
- G01N2800/044—Hyperlipemia or hypolipemia, e.g. dyslipidaemia, obesity
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Chemical & Material Sciences (AREA)
- Urology & Nephrology (AREA)
- Food Science & Technology (AREA)
- General Physics & Mathematics (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Pathology (AREA)
- Cell Biology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biophysics (AREA)
- Endocrinology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Toxicology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Management, Administration, Business Operations System, And Electronic Commerce (AREA)
- Measuring Pulse, Heart Rate, Blood Pressure Or Blood Flow (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2003434151 | 2003-12-26 | ||
| JP2004168849 | 2004-06-07 | ||
| PCT/JP2004/019758 WO2005064344A1 (ja) | 2003-12-26 | 2004-12-24 | 脂質代謝異常症の予測方法 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE472102T1 true ATE472102T1 (de) | 2010-07-15 |
Family
ID=34742146
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT04808108T ATE472102T1 (de) | 2003-12-26 | 2004-12-24 | Verfahren zur vorhersage von anomalien des lipidmetabolismus |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US7399638B2 (de) |
| EP (1) | EP1710585B1 (de) |
| JP (1) | JP4555779B2 (de) |
| AT (1) | ATE472102T1 (de) |
| DE (1) | DE602004027839D1 (de) |
| WO (1) | WO2005064344A1 (de) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK1909561T3 (da) * | 2005-07-25 | 2010-07-19 | Basf Se | Fremgangsmåde til tilvejebringelse og analyse af en animalsk population, som har et i det væsentlige identisk metabolom |
| JP5005955B2 (ja) * | 2006-05-24 | 2012-08-22 | 田辺三菱製薬株式会社 | 被験物質の脂質代謝異常症誘発可能性を予測する方法 |
| US20110162437A1 (en) * | 2006-10-09 | 2011-07-07 | Lucette Doessegger | Biomarker for Mitochondrial Toxicity Associated with Phospholipidosis |
| FI119745B (fi) * | 2006-12-05 | 2009-02-27 | Paavo Kinnunen | Menetelmä aineen fosfolipidoosia aiheuttavien ominaisuuksien ennustamiseksi |
| WO2009026153A1 (en) * | 2007-08-17 | 2009-02-26 | Metabolon, Inc. | Biomarkers for alzheimer's disease and methods using the same |
| JP5051617B2 (ja) * | 2007-12-17 | 2012-10-17 | 富士電機株式会社 | 遠心分離方法及び遠心分離装置 |
| US8313949B2 (en) * | 2009-04-16 | 2012-11-20 | Nextcea Inc. | Detecting phospholipidosis and diagnosing lysosomal storage disorders |
| US9459267B2 (en) * | 2014-05-12 | 2016-10-04 | Quest Diagnostics Investments Incorporated | Quantitation of tamoxifen and metabolites thereof by mass spectrometry |
| JP6051257B2 (ja) * | 2015-04-15 | 2016-12-27 | ライオン株式会社 | 脂質異常症への罹患しやすさを試験する方法 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5100807A (en) | 1987-10-19 | 1992-03-31 | Abbott Laboratories | Phenylacetylglutamine (pag) analytical test |
| JPH07104351B2 (ja) | 1988-09-29 | 1995-11-13 | 株式会社日本抗体研究所 | 脂質代謝異常検出用キット |
| JPH11343300A (ja) | 1998-03-13 | 1999-12-14 | Tetsuro Fujita | 新規ハプテン、それを認識する抗体およびそれらを用いた免疫学的測定法 |
| EP1142996B1 (de) | 1998-12-22 | 2009-02-25 | Daiichi Pure Chemicals Co., Ltd. | Monoklonaler antikörper gegen apolipoprotein a-i |
| US6306603B1 (en) | 1999-01-08 | 2001-10-23 | Wakunaga Phaemaceutical Co., Ltd. | CD36 mutant gene and methods for diagnosing diseases caused by abnormal lipid metabolism and diagnostic kits therefor |
| JP2001149082A (ja) * | 1999-01-08 | 2001-06-05 | Wakunaga Pharmaceut Co Ltd | Ｃｄ３６変異遺伝子並びに脂質代謝異常により引き起こされる疾患の判定法および診断キット |
| JP2001066314A (ja) * | 1999-06-23 | 2001-03-16 | E Miller Norman | 脂質代謝異常の検出方法及びこれを用いる疾病の検出方法 |
-
2004
- 2004-12-24 DE DE602004027839T patent/DE602004027839D1/de not_active Expired - Lifetime
- 2004-12-24 JP JP2005516727A patent/JP4555779B2/ja not_active Expired - Fee Related
- 2004-12-24 EP EP04808108A patent/EP1710585B1/de not_active Expired - Lifetime
- 2004-12-24 AT AT04808108T patent/ATE472102T1/de not_active IP Right Cessation
- 2004-12-24 US US10/584,366 patent/US7399638B2/en not_active Expired - Fee Related
- 2004-12-24 WO PCT/JP2004/019758 patent/WO2005064344A1/ja not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| EP1710585A4 (de) | 2008-02-20 |
| US20070166829A1 (en) | 2007-07-19 |
| JPWO2005064344A1 (ja) | 2007-07-19 |
| WO2005064344A1 (ja) | 2005-07-14 |
| JP4555779B2 (ja) | 2010-10-06 |
| DE602004027839D1 (de) | 2010-08-05 |
| EP1710585A1 (de) | 2006-10-11 |
| US7399638B2 (en) | 2008-07-15 |
| EP1710585B1 (de) | 2010-06-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Tomat et al. | Imaging mobile zinc in biology | |
| Brown et al. | Metabolomics and age-related macular degeneration | |
| MA29282B1 (fr) | Procede de diagnostic d'une steatose hepatique au moyen de marqueurs biochimiques | |
| Gailus-Durner* et al. | Systemic first-line phenotyping | |
| ATE420204T1 (de) | Verfahren zur detektion von erkrankungen | |
| RU2011129747A (ru) | Способы, относящиеся к модифицированным гликанам | |
| NO20050186L (no) | Oligosakkaridbiomarkorer for mucopolysakkaridoser og andre beslektede forstyrrelser | |
| ATE472102T1 (de) | Verfahren zur vorhersage von anomalien des lipidmetabolismus | |
| WO2002093129A3 (en) | Methods for analyzing interactions between proteins in live and intact cells | |
| Piechocka et al. | Chromatographic strategies for the determination of aminothiols in human saliva | |
| Emson et al. | A pilot study demonstrating a non-invasive method for the measurement of protein turnover in skin disorders: application to psoriasis | |
| DE60217351D1 (de) | Verfahren zur identifizierung von proben eines säugetiers als auch ein kit zur durchführung des verfahrens | |
| EP1543331A4 (de) | Verfahren zur diagnose von morbus alzheimer | |
| DK1043587T3 (da) | Fremgangsmåde til undersøgelse af nyresygdomme | |
| DE60317070D1 (de) | Verfahren zur diagnose von multipler sklerose | |
| CN101646941B (zh) | 使用硬骨鱼体内筛选心脏毒性剂的方法 | |
| BR0111975A (pt) | Fator, composição, veìculo, ligando, kits de diagnósticos, processos para detectar uma prpsc em uma amostra, e para remover prpsc de material biológico, método para diagnosticar encefalopatias espongiformes humanas transmissìveis e encefalopatias de prìons de animais, e, uso de um fator | |
| IL175692A0 (en) | Method for diagnosing diseases based on levels of anti-glycan antibodies | |
| Uchigashima et al. | Single-cell synaptome mapping of endogenous protein subpopulations in mammalian brain | |
| US10324100B2 (en) | Method for quantifying plasmalogens using PLA1 processing | |
| WO2004092728A3 (en) | Methods of measuring the ability of a test compound to inactivate a biological target in cells of a subject | |
| JP6017724B1 (ja) | 十二指腸液試料の膵液由来成分検出用試料としての適性評価方法 | |
| Puangploy et al. | Development of fluorescent phycocyanin-Cu2+ chemosensor for detection of homocysteine | |
| Dorlhiac et al. | Leveraging isotopologues as a general strategy to image neurotransmitters with vibrational microscopy | |
| Mokaila | Characterisation of cardiac protein changes post death: pilot study |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |